B+
Bull case
30%
Probability
Target price
$112.00
+4.2% vs current
CVS
CVS HealthBNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$100.00
-7.0% vs current
B-
Bear case
20%
Probability
Target price
$84.00
-21.8% vs current
AI sentiment snapshot
Latest data as of 2026-06-06
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+39.5
Score
AI commentary
The tone is modestly positive after the Q1 beat/raise, but the packet lacks quantified social, options, short-interest, or employee-sentiment inputs, so this is a low-resolution buzz read rather than a crowded-sentiment setup. Recent headlines around CVS's guidance raise and related healthcare coverage keep attention elevated, but there is no evidence here that analyst revisions have turned meaningfully more bullish yet.
RankAlpha Sentiment Codex - 2026-06-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06eventQ1 2026 beat and full-year guidance raiseMedium impact
First-quarter revenue rose 6.2% to $100.4B, GAAP EPS was $2.30, adjusted EPS was $2.57, and management raised FY26 GAAP EPS, adjusted EPS, and cash-flow guidance, which is the cleanest near-term fundamental support in the packet [#SEC-8K-2026-05-06].
2026-06-30catalystNear-term upside is capped if elevated cost trends stay stickyMedium impact
Management still described the rest of 2026 cautiously because continued elevated cost trends and potential macro headwinds could slow further margin recovery, so the post-print upside path remains execution-dependent [#SEC-8K-2026-05-06].
2026-12-31catalystSustained Health Care Benefits recovery can extend the earnings baseHigh impact
The company said Q1 adjusted EPS improvement was primarily driven by better Health Care Benefits operating income and that the full-year raise reflects improvement in Health Care Benefits and Pharmacy & Consumer Wellness; if that mix holds through year-end, CVS can sustain a higher earnings base and stronger cash generation [#SEC-8K-2026-05-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-06 • Updated nightlySource: Internal modelMethodology